Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05072080 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
A Phase 3 study of Chikungunya Virus, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,258
- Enrollment target
- 20
- Study locations
NCT05072080: Completed Phase 3 study of Chikungunya Virus, sponsored by Bavarian Nordic.
NCT05072080 is a Phase 3 study of Chikungunya Virus that has completed, run by Bavarian Nordic. The registered enrollment target is 3,258 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (322% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05072080, a Phase 3 study of Chikungunya Virus, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,258 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
Primary Outcome
Incidence of solicited AEs through Day 8 for PXVX0317 (CHIKV VLP vaccine) and placebo for all age strata combined (safety population).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CHIKV VLP/adjuvant
Study Locations (20)
Florida
- Jacksonville Center for Clinical Research - Jacksonville
- Accel Research Sites-DeLand Clinical Research Unit - Lake Mary
- Optimal Research, LLC - Melbourne
- Suncoast Research Associates, LLC - Miami
- Synexus Clinical Research US, Inc. - Pinellas Park
- Palm Beach Research Center - West Palm Beach
Kansas
- Johnson County ClinTrials - Lenexa
- Alliance for Multispecialty Research, LLC - Newton
- Alliance for Multispecialty Research - Wichita East - Wichita
Alabama
- Optimal Research, LLC - Huntsville
- Alliance for Multispecialty Research - Mobile - Mobile
California
- Velocity Clinical Research, Banning - Banning
- Optimal Research, LLC - San Diego
Illinois
- Synexus Clinical Research US, Inc. - Chicago
- Optimal Research LLC - Peoria
Arizona
- Alliance for Multispecialty Research, LLC - Tempe
Colorado
- Lynn Institute of the Rockies - Colorado Springs
Georgia
- Emory University School of Medicine - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,258 participants |
| Start Date | 2021-09-29 |
| Est. Completion | 2023-04-03 |
| Phase | Phase 3 |
What the finished NCT05072080 record still lists
NCT05072080 is an interventional study that assigns participants to a tested intervention. Its 3,258 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (322% higher).
The record links to 1 condition, with Chikungunya Virus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05072080 names 20 study sites across 10 states, led by Florida, Kansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT05072080 about?
NCT05072080 is a clinical study titled "A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)". The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 (CHIKV VLP vaccine) in healthy adult and adolescent subjects.
What is the current status of trial NCT05072080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,258 participants. The study started on 2021-09-29. Estimated completion is 2023-04-03.
What conditions does trial NCT05072080 study?
This clinical trial studies the following conditions: Chikungunya Virus.
What interventions are being tested in trial NCT05072080?
The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP/adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05072080?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05072080 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chikungunya Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05072080's enrollment target sits among peer trials
3,258 73rd of 2000 higher than 1,928 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
- NCT06953375 · 3,250 participants · NA
Implementation of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI